Opiorphin

Source: Wikipedia, the free encyclopedia.
Opiorphin[1]
Names
IUPAC name
(2S,5S,8S,11S,14S)-14,17-diamino-8-benzyl-2,11-bis(3-guanidinopropyl)-5-(hydroxymethyl)-4,7,10,13,17-pentaoxo-3,6,9,12-tetraazaheptadecan-1-oic acid
Other names
Gln-Arg-Phe-Ser-Arg; L-Glutaminyl-L-arginyl-L-phenylalanyl-L-seryl-L-arginine
Identifiers
3D model (
JSmol
)
ChEMBL
ChemSpider
  • InChI=1S/C29H48N12O8/c30-17(10-11-22(31)43)23(44)38-18(8-4-12-36-28(32)33)24(45)40-20(14-16-6-2-1-3-7-16)25(46)41-21(15-42)26(47)39-19(27(48)49)9-5-13-37-29(34)35/h1-3,6-7,17-21,42H,4-5,8-15,30H2,(H2,31,43)(H,38,44)(H,39,47)(H,40,45)(H,41,46)(H,48,49)(H4,32,33,36)(H4,34,35,37)/t17-,18-,19-,20-,21-/m0/s1 ☒N
    Key: TWWFCOBVAKAKIT-SXYSDOLCSA-N ☒N
  • InChI=1/C29H48N12O8/c30-17(10-11-22(31)43)23(44)38-18(8-4-12-36-28(32)33)24(45)40-20(14-16-6-2-1-3-7-16)25(46)41-21(15-42)26(47)39-19(27(48)49)9-5-13-37-29(34)35/h1-3,6-7,17-21,42H,4-5,8-15,30H2,(H2,31,43)(H,38,44)(H,39,47)(H,40,45)(H,41,46)(H,48,49)(H4,32,33,36)(H4,34,35,37)/t17-,18-,19-,20-,21-/m0/s1
    Key: TWWFCOBVAKAKIT-SXYSDOLCBM
  • O=C([C@H](CO)NC([C@H](CC1=CC=CC=C1)NC([C@H](CCCNC(N)=N)NC([C@H](CCC(N)=O)N)=O)=O)=O)N[C@H](C(O)=O)CCCNC(N)=N
Properties
C29H48N12O8
Molar mass 692.779 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Opiorphin is an

polypeptide, Gln-Arg-Phe-Ser-Arg (QRFSR).[3][4][5][6][7][8][9][10]

Opiorphin pentapeptide originates from the

proteases: neutral ecto-endopeptidase (MME), ecto-aminopeptidase N (ANPEP)[3]
and perhaps also a dipeptidyl peptidase DPP3.[8] Such action extends the duration of enkephalin effect where the natural pain killers are released physiologically in response to specific potentially painful stimuli, in contrast with administration of narcotics, which floods the entire body and causes many undesirable adverse reactions, including addiction liability and constipation.[11][12] In addition, opiorphin may exert anti-depressive[13][14] and antipanic action.[15]

Therapeutic application of opiorphin in humans would require modifying the molecule to avoid its rapid degradation in the intestine and its poor penetration of the blood–brain barrier.[11][12] This modification is done in the body by transformation of N-terminal glutamine into pyroglutamate. This form preserves the analgesic properties of opiorphin but with increased pharmaceutical stability.[16]

See also

References